Table 1. The case-mix of included patients stratified by HAS-BLED scores at baseline.
| Variable | Level | HAS-BLED = 0 (n = 4,150) | HAS-BLED = 1–2 (n = 40,620) | HAS-BLED >2 (n = 31,332) | Total (n = 76,102) |
|---|---|---|---|---|---|
| Age | 20–49 | 971 (23.4) | 1,165 (2.9) | 106 (0.3) | 2,242 (2.9) |
| 50–64 | 3,179 (76.6) | 9,278 (22.8) | 1,225 (3.9) | 13,682 (18.0) | |
| 65–74 | 0 (0.0) | 13,264 (32.7) | 11,129 (35.5) | 24,393 (32.1) | |
| 75–100 | 0 (0.0) | 16,913 (41.6) | 18,872 (60.2) | 35,785 (47.0) | |
| Female | yes | 1,003 (24.2) | 18,336 (45.1) | 15,068 (48.1) | 34,407 (45.2) |
| Congestive heart failure | yes | 756 (18.2) | 15,617 (38.4) | 15,291 (48.8) | 31,664 (41.6) |
| Hypertension | yes | 0 (0.0) | 20,684 (50.9) | 28,796 (91.9) | 49,480 (65.0) |
| Diabetes | yes | 182 (4.4) | 4,028 (9.9) | 6,230 (19.9) | 10,440 (13.7) |
| Previous stroke | yes | 0 (0.0) | 1,817 (4.5) | 9,126 (29.1) | 10,943 (14.4) |
| Vascular disease | yes | 48 (1.2) | 2,504 (6.2) | 5,630 (18.0) | 8,182 (10.8) |
| Abnormal renal function | yes | 0 (0.0) | 267 (0.7) | 2,526 (8.1) | 2,793 (3.7) |
| Abnormal liver function | yes | 0 (0.0) | 123 (0.3) | 660 (2.1) | 783 (1.0) |
| Previous major bleeding | yes | 0 (0.0) | 757 (1.9) | 4,132 (13.2) | 4,889 (6.4) |
| Drug consumption | yes | 0 (0.0) | 11,457 (28.2) | 28,192 (90.0) | 39,649 (52.1) |
| Alcohol abuse | yes | 0 (0.0) | 505 (1.2) | 1,340 (4.3) | 1,845 (2.4) |
| Type of anticoagulant | Vitamin K antagonist | 2,664 (64.2) | 24,113 (59.4) | 18,866 (60.2) | 45,643 (60.0) |
| Direct oral anticoagulant | 1,481 (35.7) | 16,445 (40.5) | 12,422 (39.6) | 30,348 (39.9) | |
| Indeterminable | 5 (0.1) | 62 (0.2) | 44 (0.1) | 111 (0.1) | |
| CHA2DS2VASc score | 0 | 2,489 (60.0) | 924 (2.3) | 6 (0.0) | 3,419 (4.5) |
| 1 | 1,350 (32.5) | 5,705 (14.0) | 169 (0.5) | 7,224 (9.5) | |
| > = 2 | 311 (7.5) | 33,991 (83.7) | 31,157 (99.4) | 65,459 (86.0) |